Table 5 Treatments in patients with severe CRS.
COVID-19 (N = 40) | CAR-T (N = 41) | P value | |
|---|---|---|---|
Oxygen support, n (%) | <0.001 | ||
No need for oxygen therapy | 0 (0) | 12 (29.3%) | |
Nasal cannula | 0 (0) | 15 (36.6%) | |
Non-invasive ventilation or high-flow nasal cannula | 25 (62.5%) | 12 (29.3%) | |
Invasive mechanical ventilation | 4 (10%) | 2 (4.9%) | |
Invasive mechanical ventilation and ECMO | 11 (27.5%) | 0 (0) | |
sCRS treatment, n (%) | <0.001 | ||
Corticosteroids only | 19 (47.5%) | 5 (12.2%) | |
Tocilizumab only | 0 (0) | 20 (48.8%) | |
Corticosteroids and tocilizumab | 0 (0) | 7 (17.1%) | |
Artificial-liver blood-purification only | 1 (2.5%) | 0 (0) | |
Corticosteroids and artificial-liver blood-purification | 13 (32.5%) | 0 (0) |
